title: Successful Cost-Effective Prevention of Cytomegalovirus Disease in Kidney Transplant Recipients Using Low-Dose Valganciclovir.
abstract: OBJECTIVE
  Low-dose valganciclovir prophylaxis is still under investigation in renal transplant procedures. Our aim was to assess the cost effectiveness of 450 mg versus 900 mg valganciclovir prophylaxis in kidney transplant recipients.
  
  
  METHODS
  In this prospective trial, 201 kidney transplant patients were randomized (1:1) to receive 450 mg/d (group 1, n = 100) or 900 mg/d (group 2, n = 101) valganciclovir prophylaxis for the first 6 months after transplant. Patients were studied for incidence of cytomegalovirus disease, leucopenia episodes, rejection episodes, and graft outcomes along with associated costs over 1 year. Costs (in US dollars) of treatment of rejection were also analyzed.
  
  
  RESULTS
  Demographic features of the studied groups were comparable. We found that the cost of cytomegalovirus care in group 1 patients was significantly lower (by 50% at 6 months; P < .001), with less leukopenia episodes (P = .04), lower doses of granulocyte colony-stimulating factor (by 30% at 6 months; P = .03), higher doses of mycophenolate mofetil (P = .04), and less rejection episodes (P = .01) compared with group 2. In group 2, there were more episodes of cytomegalovirus infection (P = .052) and BK virus nephropathy (P = .04). Graft and patient outcomes were satisfactory in both groups.
  
  
  CONCLUSIONS
  Low-dose valganciclovir for cytomegalovirus prophylaxis after renal transplant is safer, effective and without breakthrough infection, and less costly than using the usual dose.
authors.affiliation: Urology and Nephrology Center, Mansoura University, Mansoura, Egypt; Hamed Al-Essa Organ Transplant Center, Sabah Area, Kuwait.
authors.forename: Osama
authors.initials: O
authors.lastname: Gheith
authors.forename: Medhat A
authors.initials: MA
authors.lastname: Halim
authors.forename: Torki
authors.initials: T
authors.lastname: Al-Otaibi
authors.forename: Hany
authors.initials: H
authors.lastname: Mansour
authors.forename: Ahmed
authors.initials: A
authors.lastname: Mosaad
authors.forename: Hassanein Abo
authors.initials: HA
authors.lastname: Atteya
authors.forename: Zakaria
authors.initials: Z
authors.lastname: Zakaria
authors.forename: Tarek
authors.initials: T
authors.lastname: Said
authors.forename: Prasad
authors.initials: P
authors.lastname: Nair
authors.forename: Narayanam
authors.initials: N
authors.lastname: Nampoory
mesh_terms: D000328:Adult; D000998:Antiviral Agents / Q000008:administration & dosage* / Q000191:economics*; D003362:Cost-Benefit Analysis; D003586:Cytomegalovirus Infections / Q000175:diagnosis / Q000191:economics* / Q000517:prevention & control* / Q000821:virology; D004334:Drug Administration Schedule; D016527:Drug Costs; D005260:Female; D015774:Ganciclovir / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000191:economics; D006801:Humans; D007166:Immunosuppressive Agents / Q000191:economics / Q000627:therapeutic use; D016030:Kidney Transplantation / Q000009:adverse effects / Q000191:economics*; D008297:Male; D008875:Middle Aged; D011446:Prospective Studies; D013997:Time Factors; D016896:Treatment Outcome; D000077562:Valganciclovir
chemical_list: D000998:Antiviral Agents; D007166:Immunosuppressive Agents; D000077562:Valganciclovir; D015774:Ganciclovir